AR124297A1 - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents
Ácidos pirazol piperidin carboxílicos sustituidosInfo
- Publication number
- AR124297A1 AR124297A1 ARP210103422A ARP210103422A AR124297A1 AR 124297 A1 AR124297 A1 AR 124297A1 AR P210103422 A ARP210103422 A AR P210103422A AR P210103422 A ARP210103422 A AR P210103422A AR 124297 A1 AR124297 A1 AR 124297A1
- Authority
- AR
- Argentina
- Prior art keywords
- diseases
- hfref
- salts
- represents hydrogen
- heart
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 208000008960 Diabetic foot Diseases 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 2
- 229910052799 carbon Chemical group 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- KPVQNXLUPNWQHM-RBEMOOQDSA-N 3-acetylpyridine adenine dinucleotide Chemical compound CC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 KPVQNXLUPNWQHM-RBEMOOQDSA-N 0.000 abstract 1
- CANSPPZTVXEOJH-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxylic acid Chemical class C1CCNC2=C1NN=C2C(=O)O CANSPPZTVXEOJH-UHFFFAOYSA-N 0.000 abstract 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a ácidos carboxílicos pirazolo piperidínicos sustituidos, sus sales y a los procesos para su preparación, así como a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular enfermedades cardiovasculares y cardíacas, preferentemente insuficiencia cardíaca con fracción de eyección reducida y conservada (ICFEr, ICFEp e ICFErm), hipertensión (HTA), enfermedades arteriales periféricas (EAP, EAPO), enfermedad renal o síndrome cardiorrenal, preferentemente enfermedad renal crónica y diabética (ERC y ERD), enfermedades cardiopulmonares y pulmonares, preferentemente hipertensión pulmonar (HP), y otras enfermedades, preferentemente enfermedades neurodegenerativas y diferentes formas de demencias, enfermedades fibróticas, esclerosis sistémica (ES), enfermedad de célula falciforme (SCD, por sus siglas en inglés), trastornos de cicatrización de heridas tales como úlcera del pie diabético (UPD). Reivindicación 1: El compuesto de la fórmula (1), en la cual R¹ representa hidrógeno o halógeno, R² representa hidrógeno o halógeno, R³ representa cloro o trifluorometilo, R⁴ representa hidrógeno o alquilo C₁₋₄ R⁵ representa alquilo C₁₋₆ X¹ representa nitrógeno o carbono X² representa nitrógeno o carbono o una de sus sales, sus solvatos o solvatos de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124297A1 true AR124297A1 (es) | 2023-03-15 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103422A AR124297A1 (es) | 2020-12-10 | 2021-12-09 | Ácidos pirazol piperidin carboxílicos sustituidos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240051935A1 (es) |
| EP (1) | EP4259617A1 (es) |
| JP (1) | JP2023552583A (es) |
| KR (1) | KR20230118144A (es) |
| CN (1) | CN116710439A (es) |
| AR (1) | AR124297A1 (es) |
| AU (1) | AU2021393988A1 (es) |
| CA (1) | CA3204495A1 (es) |
| CL (1) | CL2023001632A1 (es) |
| CO (1) | CO2023007335A2 (es) |
| CR (1) | CR20230242A (es) |
| DO (1) | DOP2023000115A (es) |
| EC (1) | ECSP23040828A (es) |
| IL (1) | IL303296A (es) |
| MX (1) | MX2023006903A (es) |
| PE (1) | PE20231501A1 (es) |
| TW (1) | TW202237589A (es) |
| WO (1) | WO2022122914A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| PE20130683A1 (es) | 2010-02-27 | 2013-06-20 | Bayer Ip Gmbh | Ariltriazolonas ligadas a bisarilo y su uso |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CA2804470A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| ES2697902T3 (es) | 2014-11-03 | 2019-01-29 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
-
2021
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko unknown
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en active Application Filing
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 EP EP21823605.7A patent/EP4259617A1/en active Pending
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022122914A1 (en) | 2022-06-16 |
| CA3204495A1 (en) | 2022-06-16 |
| EP4259617A1 (en) | 2023-10-18 |
| MX2023006903A (es) | 2023-06-26 |
| AU2021393988A1 (en) | 2023-06-22 |
| ECSP23040828A (es) | 2023-07-31 |
| CR20230242A (es) | 2023-07-19 |
| KR20230118144A (ko) | 2023-08-10 |
| CL2023001632A1 (es) | 2023-11-10 |
| US20240051935A1 (en) | 2024-02-15 |
| DOP2023000115A (es) | 2023-07-16 |
| CN116710439A (zh) | 2023-09-05 |
| JP2023552583A (ja) | 2023-12-18 |
| IL303296A (en) | 2023-07-01 |
| TW202237589A (zh) | 2022-10-01 |
| PE20231501A1 (es) | 2023-09-26 |
| CO2023007335A2 (es) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124297A1 (es) | Ácidos pirazol piperidin carboxílicos sustituidos | |
| AR124196A1 (es) | Ácidos pirazolo piperidin carboxílicos sustituidos | |
| EA201171361A1 (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
| RU2016101964A (ru) | СТИМУЛЯТОРЫ sGC | |
| ATE516285T1 (de) | Dihydropyridinonderivate | |
| NO20061340L (no) | Anvendelse av fumarsyrederivater for behandling av hjerteinsuffisiens og astma | |
| AR061996A1 (es) | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular | |
| JP2011518178A5 (es) | ||
| JP2011527994A5 (es) | ||
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| JP2013511556A5 (es) | ||
| JP2009543844A5 (es) | ||
| RU2015105603A (ru) | Антагонисты минералокортикоидных рецепторов | |
| EA202191150A1 (ru) | Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции | |
| JP2005515994A5 (es) | ||
| Ronco | Cardio-renal syndromes: from foggy bottoms to sunny hills | |
| JP2011509920A5 (es) | ||
| AR098788A1 (es) | Piperidinil-tetrahidroquinolinas sustituidas | |
| JP2011530604A5 (es) | ||
| Patel et al. | Role of tranexamic acid for reducing blood loss in tetralogy of fallot | |
| RU2021129263A (ru) | Пути применения ингибиторов фосфодиэстеразы | |
| RU2021111847A (ru) | Средство для ингибирования метастазирования в легких | |
| Patel et al. | Predictive Modeling of Phenylpiperazine Derivatives for Renin Inhibition: QSAR Study of Phenylpiperazine Derivatives as Renin Inhibitors | |
| WO2011065444A1 (ja) | 抗血栓剤 | |
| BR112022021862A2 (pt) | Aperfeiçoadores de transdução inovadores e usos dos mesmos |